Relapsed Diffuse Large B-Cell Lymphoma: Clinical Trials

1 trial for Relapsed Diffuse Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1

Follow Relapsed Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-Cell Lymphoma trials Research Report on Relapsed Diffuse Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
400mg ABT-199, Ibrutinib, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1TerminatedHackensack Meridian Health102017-09-052024-09-23

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (1)

Broader conditions

Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Interventions

Rituximab (1)  ·  ibrutinib (1)  ·  venetoclax (1)

Sponsors

Hackensack Meridian Health (1)

Countries

United States (1)

Top investigators

Andre Goy, MD (1)